Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Intervalo de año de publicación
1.
Microb Pathog ; 186: 106488, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-38061668

RESUMEN

Trypanosoma cruzi parasite - causal Chagas disease agent - affects about 7 million people; no vaccine is available, and current medications have not been entirely effective. Multidisciplinary efforts are necessary for developing clinical vaccine prototypes. Thus, this research study aims to assess the expressed and whole-cell administration protection of the oral vaccine prototype Tc24:Co1 using Schizochytrium sp. microalga. High recombinant protein expression yields (675 µg/L) of algal culture were obtained. Additionally, Schizochytrium sp.-Tc24:Co1 resulted stable at 4 °C for up to six months and at 25 °C for three months. After receiving four oral doses of the vaccine, the mice showed a significant humoral immune response and a parasitemia reduction associated with a lack of heart inflammatory damage compared with the unvaccinated controls. The Schizochytrium sp.-Tc24:Co1 vaccine demonstrates to be promising as a prototype for further development showing protective effects against a T. cruzi challenge in a mouse model.


Asunto(s)
Enfermedad de Chagas , Vacunas Antiprotozoos , Trypanosoma cruzi , Humanos , Animales , Ratones , Enfermedad de Chagas/tratamiento farmacológico , Proteínas Recombinantes , Modelos Animales de Enfermedad
2.
Exp Parasitol ; 249: 108519, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37004860

RESUMEN

Leishmaniasis is a vector-borne neglected tropical disease caused by the Leishmania spp. Parasite. The disease is transmitted to humans and animals by the bite of infected female sandflies during the ingestion of bloodmeal. Because current drug treatments induce toxicity and parasite resistance, there is an urgent need to evaluate new drugs. Most therapeutics target the differentiation of promastigotes to amastigotes, which is necessary to maintain Leishmania infection. However, in vitro assays are laborious, time-consuming, and depend on the experience of the technician. In this study, we aimed to establish a short-term method to assess the differentiation status of Leishmania mexicana (L. mexicana) using flow cytometry. Here, we showed that flow cytometry provides a rapid means to quantify parasite differentiation in cell culture as reliably as light microscopy. Interestingly, we found using flow cytometry that miltefosine reduced promastigote-to-amastigote differentiation of L. mexicana. We conclude that flow cytometry provides a means to rapidly assay the efficacy of small molecules or natural compounds as potential anti-leishmanials.


Asunto(s)
Leishmania mexicana , Leishmania , Leishmaniasis , Humanos , Animales , Femenino , Leishmania mexicana/fisiología , Citometría de Flujo , Diferenciación Celular
3.
Parasit Vectors ; 7: 361, 2014 Aug 09.
Artículo en Inglés | MEDLINE | ID: mdl-25108307

RESUMEN

BACKGROUND: Cutaneous leishmaniasis is a tropical disease affecting over one million patients annually and Leishmania (L.) mexicana is one of the major etiological agents in the Americas. Here we established the first experimental infection of L. (L.) mexicana in canids. METHODS: Beagle dogs were infected intradermally with culture-derived L. (L.) mexicana. We followed skin ulcer development, histopathological signs, parasite burden and the immune status of the infected dogs. RESULTS: All infected dogs developed uniform oval-craterform ulcers similar to those observed in humans, associated with mixed T helper 1/T helper 2 immune responses. Parasites were detected in the healed lesions 15 weeks post-infection. Higher anti-Leishmania IgG levels correlated with larger lesions and high IgG1/IgG2 ratio was associated with some level of splenomegaly. CONCLUSIONS: The canine model described in this work will be of use for further understanding of L. (L.) mexicana immunopathogenensis, and for drug and vaccine development.


Asunto(s)
Modelos Animales de Enfermedad , Leishmania mexicana , Leishmaniasis Cutánea/parasitología , Animales , Perros , Leishmaniasis Cutánea/patología
4.
Mem Inst Oswaldo Cruz ; 108(2): 172-7, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-23579796

RESUMEN

Peromyscus yucatanicus (Rodentia: Cricetidae) is a primary reservoir of Leishmania (Leishmania) mexicana (Kinetoplastida: Trypanosomatidae). Nitric oxide (NO) generally plays a crucial role in the containment and elimination of Leishmania. The aim of this study was to determine the amount of NO produced by P. yucatanicus infected with L. (L.) mexicana. Subclinical and clinical infections were established in P. yucatanicus through inoculation with 1 x 10 2 and 2.5 x 10 6 promastigotes, respectively. Peritoneal macrophages were cultured alone or co-cultured with lymphocytes with or without soluble Leishmania antigen. The level of NO production was determined using the Griess reaction. The amount of NO produced was significantly higher (p ≤ 0.0001) in co-cultured macrophages and lymphocytes than in macrophages cultured alone. No differences in NO production were found between P. yucatanicus with subclinical L. (L.) mexicana infections and animals with clinical infections. These results support the hypothesis that the immunological mechanisms of NO production in P. yucatanicus are similar to those described in mouse models of leishmaniasis and, despite NO production, P. yucatanicus is unable to clear the parasite infection.


Asunto(s)
Leishmania mexicana/inmunología , Leishmaniasis Cutánea/inmunología , Macrófagos Peritoneales/parasitología , Óxido Nítrico/biosíntesis , Peromyscus/metabolismo , Animales , Modelos Animales de Enfermedad , Macrófagos Peritoneales/inmunología , Peromyscus/parasitología
5.
Mem. Inst. Oswaldo Cruz ; 108(2): 172-177, abr. 2013. tab, graf
Artículo en Inglés | LILACS | ID: lil-670406

RESUMEN

Peromyscus yucatanicus (Rodentia: Cricetidae) is a primary reservoir of Leishmania (Leishmania) mexicana (Kinetoplastida: Trypanosomatidae). Nitric oxide (NO) generally plays a crucial role in the containment and elimination of Leishmania. The aim of this study was to determine the amount of NO produced by P. yucatanicus infected with L. (L.) mexicana. Subclinical and clinical infections were established in P. yucatanicus through inoculation with 1 x 10 2 and 2.5 x 10 6 promastigotes, respectively. Peritoneal macrophages were cultured alone or co-cultured with lymphocytes with or without soluble Leishmania antigen. The level of NO production was determined using the Griess reaction. The amount of NO produced was significantly higher (p ≤ 0.0001) in co-cultured macrophages and lymphocytes than in macrophages cultured alone. No differences in NO production were found between P. yucatanicus with subclinical L. (L.) mexicana infections and animals with clinical infections. These results support the hypothesis that the immunological mechanisms of NO production in P. yucatanicus are similar to those described in mouse models of leishmaniasis and, despite NO production, P. yucatanicus is unable to clear the parasite infection.


Asunto(s)
Animales , Leishmania mexicana/inmunología , Leishmaniasis Cutánea/inmunología , Macrófagos Peritoneales/parasitología , Óxido Nítrico/biosíntesis , Peromyscus/metabolismo , Modelos Animales de Enfermedad , Macrófagos Peritoneales/inmunología , Peromyscus/parasitología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA